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Stroke remains a significant problem despite de-
cades of work on neuroprotective strategies. NMDA
receptor (NMDAR) antagonists are neuroprotective
in preclinical models, but have been clinically unsuc-
cessful, in part due to side effects. Here we describe
a prototypical GluN2B-selective antagonist with an
IC50 value that is 10-fold more potent at acidic pH
6.9 associated with ischemic tissue compared to
pH 7.6, a value close to the pH in healthy brain tissue.
This should maximize neuroprotection in ischemic
tissue while minimizing on-target side effects associ-
ated with NMDAR blockade in noninjured brain re-
gions. We have determined the mechanism underly-
ing pH-dependent inhibition and demonstrate the
utility of this approach in vivo. We also identify dicar-
boxylate dimers as a novel proton sensor in proteins.
These results provide insight into themolecular basis
of pH-dependent neuroprotective NMDAR block,
which could be beneficial in a wide range of neuro-
logical insults associated with tissue acidification.
INTRODUCTION
The highmortality andmorbidity of patients suffering fromneuro-
logical damage as a result of cerebral ischemia, stroke, sub-
arachnoid hemorrhage, or traumatic brain injury (TBI) constitute
an enormous burden on society. Despite decades of research
andmultiple clinical strategies, there are few therapeutic alterna-
tives for stroke apart fromdissolution of the vessel clot in a subset
of patients. A number of studies have shown that glutamate rises
in injured tissue in animal models and human patients (see Table
S1 available online). Virtually all neurons in the CNS express
NMDA receptors (NMDARs), and without exception, overactiva-tion of NMDARs is neurotoxic (Olney, 1969; Choi et al., 1988; Ell-
re´n and Lehmann, 1989; Mody and MacDonald 1995; Wroge
et al., 2012). Although numerous studies have confirmed the neu-
roprotective efficacy of NMDAR antagonists in animal models of
injury (Table S2), multiple clinical trials with NMDAR antagonists
failed to improve patient outcome in stroke or TBI (Table S3).
Thus, a dichotomy exists between the lack of clinical efficacy
and unequivocal preclinical data showing that NMDAR blockade
within hours of ischemia reduces neuronal death in multiple spe-
cies (Table S2). Post hoc analyses of clinical trials involving
NMDAR antagonists have identified several factors that may ac-
count for their failures (Morris et al., 1999; Albers et al., 2001;
Sacco et al., 2001; Gladstone et al., 2002; Farin and Marshall
2004). The most commonly discussed shortcomings include (1)
the presence of dose-limiting side effects that prompted reduced
therapeutic exposures, (2) the administration of NMDAR antago-
nists after an effective temporal window (several hours postin-
jury) recognized in animal studies, (3) the heterogeneity of
ischemic injuries, and (4) the lack of quantifiable clinical end-
points. The latter could be addressed with careful management
of the clinical trial, inclusion criteria, and postinjury analysis (Kid-
well et al., 2001; Narayan et al., 2002). Advances in clinical trial
design have dramatically shortened the time to administer neuro-
protectants to patients (Saver, 2013), bringing delivery in linewith
therapeutic windows for efficacy demonstrated in preclinical
studies. If clinical treatments can be delivered within 2 hr by first
responders, NMDARantagonists with expanded tolerabilitymar-
gins could become useful therapeutic agents. To improve the
tolerability profile of NMDAR antagonists, we sought to limit
GluN2B receptor antagonism to the affected regions and times
atwhichbrain injury occurs, thereby reducing overall side effects.
It has long been known that ischemia is associated with tissue
acidification as a result of altered energy production and failure
to clear tissue CO2 (Kaplan et al., 1987; Matsumoto et al.,
1990; Katsura et al., 1992). Tissue acidification can reach pH
6.9 in penumbral regions that are protected by NMDAR antago-
nists in animal models of ischemia, and pH 6.5 in the ischemic
core (Mutch and Hansen 1984; Smith et al., 1986; NedergaardNeuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc. 1305
Table 1. Optimization of pH Dependence of GluN1/GluN2B Antagonists as a Function of N-Alkyl Chain Length and Steric Bulk
Ra #
Chain
Amine pKab
Fold Increase in
Ionized Speciesc
N-Substituent
Volume Angstroms3
IC50 pH
6.9 mM (N) d
IC50 pH
7.6 mM (N) d
IC50(7.6)/IC50
(6.9) Ratio e
-H (S) 93-4 8.6 1.1 – 0.036 (10) 0.045 (11) 1.3
-CH3 (S) 93-2 8.0 1.3 19.8 0.050 (29) 0.13 (22) 2.6
-CH2CH3 (S) 93-5 8.1 1.2 33.4 0.021 (22) 0.067 (14) 3.2
-CH2CH2CH3 (S) 93-6 8.1 1.2 47.9 0.094 (17) 0.48 (16) 5.1
-CH2CH2CH2CH3 (S) 93-31 8.1 1.2 62.3 0.19 (32) 1.8 (23) 9.4
-CH2CH2CH2CH2CH3 (S) 93-87 8.1 1.2 77.5 0.16 (9) 0.60 (6) 3.8
-CH(CH3)2 (S) 93-115 8.2 1.2 47.9 0.19 (11) 0.62 (12) 3.3
-CH2CH(CH3)2 (S) 93-97 8.0 1.3 63.6 1.1 (21) 3.2 (31) 2.9
See also Figure S1 and Table S6.
aCompound synthesis described in Tahirovic et al. (2008); all compounds were the S-enantiomer.
bThe pKa of the chain nitrogen was calculated using ACD/pKa DB 12.00 (http://www.acdlabs.com).
cFold increase ionized species when reducing pH from 7.6 (pH1) to 6.9 (pH2) was calculated using Equation 3: the Henderson-Hasselbach equation as

1+ 10ðpH2pKaÞ

1+ 10ðpH1pKaÞ

: (Equation 3)
dIC50 values for inhibition of GluN1/GluN2B expressed in Xenopus oocytes were determined as described in the Experimental Procedures from com-
posite inhibition curves. N is the number of oocytes recorded; measurements were made for oocytes at both pH values in the same experiment. The
slope varied from 0.70 to 1.09; maximum inhibition 79%–100%.
eThe pH-dependent potency ratio for inhibition of GluN1/GluN2B receptors.et al., 1991; Katsura and Siesjo, 1998). We studied pH depen-
dence of GluN2B-selective NMDAR antagonists (Pahk and Wil-
liams 1997; Mott et al., 1998; Wang et al., 2014) using medicinal
chemistry to synthesize compounds that were maximally potent
and effective in ischemic tissue, yet minimally potent in healthy
brain. Our goal was to identify a novel class of clinically relevant
NMDAR antagonists with expanded tolerability/safety margins
compared to previous generations of NMDAR antagonists.
Here we describe the mechanistic and structural basis for pH-
sensitive GluN2B-selective antagonists and demonstrate their
utility as neuroprotectants in vivo.
RESULTS
pH-Sensitive GluN2B-Selective Antagonists
We evaluated the pH sensitivity of multiple GluN2B-selective
noncompetitive antagonists identified by bioinformatic criteria
as diaryl compounds with a nitrogen-containing linker and >10 A˚
separation between terminal aromatic rings (Chenard andMenniti
1999). Among these, the S-enantiomeric analogs of the propanol-
amine AM-92016 (93-2, Table 1) emerged as a potent, syntheti-
cally tractable class of molecules that showed systematic varia-
tions in pH sensitivity. We subsequently evaluated the pH
dependence of over 200 analogs on rat GluN1-1a/GluN2B recep-
tors (hereafter GluN1/GluN2B) expressed in Xenopus laevis oo-
cytes (Tahirovic et al., 2008; Mosley et al., 2009), including the
series of N-alkyl-substituted analogs summarized in Table 1.
Within this subseries, an optimal length of the N-alkyl chain, com-
pound 93-31 (four carbons), maximized the pH sensitivity and
showed an order of magnitude shift in potency per half-log unit1306 Neuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc.change in pH in Xenopus oocytes (Table 1). Figures 1A and 1B
show similar effects of pH on concentration-effect data for 93-
31 inhibition of GluN1/GluN2B receptors expressed in HEK293
cells recorded under voltage clamp. Although inhibition observed
in mammalian cells is more potent (pH 6.9, IC50 = 0.040 mM)
compared to Xenopus oocytes, the potency is enhanced 9.0-
fold at acidic pH. We subsequently tested the effects of 93-31
on triheteromericNMDARs that contain one copy each of GluN2A
and GluN2B (Hansen et al., 2014). Although triheteromeric recep-
tors show reduced sensitivity to GluN2B-selective inhibitors (Hat-
ton and Paoletti 2005; Hansen et al., 2014), compound 93-31 still
showed 4.4-fold enhanced potency at acidic pH at GluN1/
GluN2A/GluN2B receptors (Figure S1), suggesting it will retain
pH sensitivity at triheteromeric receptors expressed in adult cor-
tex. We selected compound 93-31 as a prototype to evaluate
the mechanism of pH-sensitive NMDAR inhibition.
Mechanism Underlying pH Sensitivity of GluN2B
Antagonists
One potential explanation for the pH sensitivity of 93-31 could be
a systematic change in the pKa of the tertiary amine in the diaryl
linker that could alter the fractions of ionized and unionized
ligand, and thus alter potency. This occurs with phosphono-con-
taining competitive antagonists, leading to lower concentrations
of the more active species, which reduces potencies for these
competitive antagonists under acidic conditions (Benveniste
andMayer 1992). Table 1 summarizes the predicted free solution
pKa values of the tertiary amine in this series, and shows that the
relative abundance of ionized or unionized species does not ac-
count for pH-dependent potency. In addition, we also examined
Figure 1. Proton-Sensitive Inhibition of GluN1/GluN2B NMDARs
(A) Representative whole-cell current recordings from HEK cells transiently
expressing rat GluN1/GluN2B receptors. Current responses were elicited by
100 mM glutamate (open bar) in the absence of (black) or presence of 0.3 mM
93-31 (gray) at pH 7.6 (left panel) and pH 6.9 (right panel) (VHOLD = 60 mV).
Glycine (30 mM) was present in all the recording solutions.
(B) Composite concentration-response curves at pH 7.6 and pH 6.9 for
compound 93-31 determined by whole-cell currents recorded from HEK cells
transiently expressing GluN1/GluN2B receptors.
(C) Representative whole-cell currents recorded from HEK cells transiently
expressing rat GluN1/GluN2B receptors were elicited by 100 mMglutamate and
30 mM glycine (open bar), followed by coapplication of glutamate and glycine
plus increasing concentrations of 93-31 (filled bar) at pH 6.9 (VHOLD = 60 mV).
(D) Plot of the reciprocal of the fitted time constant describing the onset of
inhibition as a function of 93-31 concentration at pH 6.9 (filled circles) and pH
7.6 (open squares) is shown with fitted linear regression superimposed. Insets
display the calculated kon, koff, and KD values at each pH. All data are pre-
sented as mean ± SEM. See also Figure S1 and Table S4.the branched chain analogs iso-propyl (93-115) and iso-butyl
(93-97), which show less pH sensitivity (Table 1). For example,
compound 93-97, the iso-butyl isomer of 93-31, showed a
similar pKa but only a 2.9-fold increase in potency at lower pH
values, compared to a 9.4-fold increase for the straight chain iso-
mer 93-31. These data exclude the possibility that pH-induced
changes in ligand ionization account for the proton sensitivity
for inhibition of GluN1/GluN2B receptors.
To investigate the mechanism underlying proton sensitivity,
we evaluated whether extracellular pH alters the rates at which
93-31 binds to and dissociates from the receptor. We expressed
GluN1/GluN2B receptors in HEK cells and performed rapid
agonist/modulator concentration jumps while recording the
whole-cell current. The onset of inhibition following application
of compound 93-31 (Figure 1C) could be well described by a sin-
gle exponential function, allowing us to determine the associa-
tion and dissociation rate constants for 93-31 at two different
pH values by analyzing the concentration dependence for onset
of inhibition (Figure 1D).
Analysis of these data suggests that increasing the proton
concentration slowed the dissociation rate kOFF and increased
the association rate kON (Figure 1D; Table S4). This decreased
the KD by 10.3-fold at pH 6.9 compared to pH 7.6. We interpret
these data to suggest that the pH sensitivity of the association
and dissociation rates (and thus binding) for compound 93-31
accounts for the proton sensitivity of the IC50 (Table S4). Given
the minimal effect of pH on ligand ionization (Table 1), agonist
EC50 (Traynelis et al., 1995), and response time course (Banke
et al., 2005), we hypothesized that the proton-sensitive inhibition
reflects altered protein conformation, or an altered set of side-
chain rotamers and/or ionization states at acidic pH that renders
compound 93-31 a more potent inhibitor.
Binding of pH-Sensitive Antagonists
To explore the structural basis for the pH sensitivity of the 93-
series compounds, we docked the compounds in Table 1 into
a model derived from crystallographic data for a structure of
Xenopus GluN1-ATD dimerized with rat GluN2B-ATD (3QEL,
Karakas et al., 2011). Figure 2 shows a high scoring pose of
93-31 docked into the ifenprodil binding site (Figures 2A–2D).
From these docking studies it is clear that 93-31 can adopt a
pose similar to that determined for ifenprodil with molecular
contacts analogous to those described for other propanol-
amines (Burger et al., 2012). For example, the chlorophenyl
ring of 93-31 overlays the phenyl ring of ifenprodil in a hydropho-
bic pocket defined by GluN1-Tyr109 and GluN2B-Phe114/Ile82
(Figures 2C and 2D), while the phenylether moiety of 93-31 is
superimposed on the phenol ring of ifenprodil and the sulfon-
amide matches the phenol hydroxyl group (Figure 2E). The ter-
tiary amine of 93-31 occupies the same region as its ifenprodil
piperidine counterpart (Figures 2B and 2E). When docking with
the central tertiary nitrogen protonated (S-enantiomer), the
ammonium group is predicted to make favorable contact with
GluN2B-Gln110 (Figure 2C), which is also simultaneously able
to interact with the ether moiety of 93-31. The hydroxyl group
is able to form a hydrogen bond with the side-chain carboxyl
of GluN2B-Glu106. All ligands shown in Table 1 docked in a
similar fashion.Neuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc. 1307
Figure 2. Binding of 93-31 to the GluN1/GluN2B ATD Heterodimers
(A) A model of the GluN1/GluN2B NMDAR built from crystallographic data for
the NMDAR (Karakas and Furukawa, 2014). The red ellipse indicates the
ifenprodil binding site within the amino-terminal domain at the interface of
GluN1 and GluN2B.
(B) Superimposed conformations of 93-31 (cyan) and ifenprodil (magenta)
docked into the ATD dimer (Karakas et al., 2011; see Experimental Pro-
cedures).
(C) The bichlorophenyl ring sits in a hydrophobic pocket defined by GluN1-
Tyr109 and GluN2B-Ile82/Phe114. The amino group is predicted to interact
with GluN2B-Gln110, and Glu106 hydrogen bonds with the hydroxyl moiety.
(D) Reversed view of 93-31 showing interactions with GluN1-Tyr109, and
GluN2B-Asp113, which is predicted to have an elevated pKa within the protein
compared to free solution.
(E) Juxtaposed functional groups of ifenprodil (3QEL) and 93-31 (from left
to right, chlorophenyl/phenyl, tertiary amine, and sulfonamide/phenol); R is
n-butyl.Examination of the binding pockets represented in structures
for ifenprodil and Ro 25-6981-bound ATD heterodimer (3QEL
and 3QEM) reveals a small 8 A˚ tunnel leading away from the
binding site interface toward the GluN1 subunit that is lined pri-
marily by hydrophobic side chains (Figures 2B and 3A). This
passageway is close to the chain nitrogen of the N-substituted1308 Neuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc.propanolamines, raising the possibility that it might be involved
in the differential properties observed for the different-sized alkyl
substituents on this nitrogen. Extensive induced-fit docking sug-
gested that the N-alkyl derivatives can occupy and exploit the
space created by this tunnel (Figure 3A). We therefore tested
whether inhibition of receptors by 93-series compounds is
altered by mutations at residues forming this tunnel, choosing
side chains for substitutions that occlude the tunnel but do not
otherwise perturb the overall protein structure (confirmed bymo-
lecular dynamics simulations, Figure S2), such asGluN1(G112A).
Modeling places the alanine side-chain methyl within the tunnel,
effectively occluding it. If the existence of this tunnel provides
additional space for N-alkyl derivatives, then occlusion should
alter IC50 for n-butyl-substituted 93-31, but not that of the unsub-
stituted analog 93-4 (Figures 3B and 3C). Concentration-effect
curves for these two inhibitors against wild-type GluN1/GluN2B
andGluN1(G112A)/GluN2Bmutant receptors in oocytes showed
that the IC50 for 93-31 was increased 6-fold at pH 6.9 from 0.19
to1.2 mM (n = 23–29 oocytes) without a change in slope (0.8–0.9)
or fitted minimum (17%–20%), consistent with the idea that this
tunnel altered the binding of this ligand. Further, the pH sensi-
tivity of 93-31 was reduced to 3.8-fold by the GluN1(G112A) mu-
tation (Figure 3D; Table 2). By contrast, 93-4 which lacks an
N-linked substitution showed only a 2-fold increase in the IC50
from 0.036 mM at wild-type GluN1/GluN2B (n = 10) compared
to 0.070 mM at GluN1(G112A)/GluN2B (n = 8) mutant receptors
with no change of pH sensitivity (1.4-fold) for inhibition (Fig-
ure 3E). These results were not a reflection of a change in the
receptor’s inherent pH sensitivity, as the ratio of maximum re-
ceptor current at pH 6.9 to 7.6 for GluN1(G112A)/GluN2B
(0.21 ± 0.01, n = 8) was identical to that for wild-type GluN1/
GluN2B (0.21 ± 0.01, n = 8, p = 0.92). These data are consistent
with the idea that ligands with N-alkyl substitutions can take
advantage of space afforded by this tunnel.
Identification of pH-Sensitive Binding-Site Residues
We next explored whether ionizable residues near the binding
site might be involved in the pH-dependent change in associa-
tion rate for 93-31. The pKa values for 20 ionizable residues in
the GluN1/GluN2B dimer (3QEL) within 12 A˚ of the ifenprodil
binding pocket were calculated (Figure 4A; Table 2). Predicted
pKa values (pKa*) for ionizable side chains caused by the sur-
rounding microenvironment suggest that some residues may
experience a locally induced pKa shift, rendering side-chain
ionization(s) sensitive to a decrease in pH to 6.9, as occurs in
the ischemic penumbra (Table 2). Among the 20 residues,
several pKa* values were predicted to be substantially elevated
relative to their free solution values, including a pair of closely
spaced acidic residues (Figures 4A and 4B), GluN2B-Glu106
(N terminus of helix-3, pKa* 7.0) and GluN2B-Glu235 (C termi-
nus of helix-8, pKa* 5.1). The side-chain rotamer of Glu235 in
a crystal structure solved at pH 7.5 (3QEL) is oriented away
from Glu106 (Figure 4B), and thus the latter only contributes a
small increase to the predicted pKa of Glu235 (DpKa* 0.8).
GluN2B-Glu106 is less solvent exposed than Glu235, and
thus is more likely to have an elevated pKa*. At pH 6.9, about
half of the Glu106 residues (pKa* 7.0) at any moment will be pro-
tonated. Protonation of either of these residues is predicted to
Figure 3. Exploitation of a GluN1 Tunnel at
the ATD Heterodimer Interface by 93-31
(A) Spacefill illustration of the tunnel entering into
GluN1 (green arrows) with an induced-fit docked
pose of 93-31 showing that the n-butyl substituent
on the chain nitrogen protrudes into and fills this
space.
(B) Occlusion of the GluN1 tunnel by the mutation
GluN1(G112A), shown as a bronze spacefill,
clashes with the n-butyl group of 93-31 in this
docked pose.
(C) The GluN1(G112A) mutation, shown as a
bronze spacefill, does not interact with docked
pose of 93-4, which lacks any substituent on the
chain nitrogen. The bichlorophenyl ring is at bot-
tom.
(D and E) Concentration effect curves for 93-31 (D)
or 93-4 (E) inhibition of GluN1/GluN2B (left panel)
and GluN1(G112A)/GluN2B (right panel) re-
sponses in oocytes. All data presented as mean ±
SEM. See text for fitted IC50 values. See also
Figure S2.allow a favorable interaction, enhanced by the formation of a
carboxylic acid dimer, if both are protonated. This hypothesis
is partially confirmed by a second crystal structure of GluN2B
at pH 5.5, in which presumably protonated Glu235 interacts
directly with Glu106 as a dimer (3JPW; Figure 4B). The local
conformational reorganization is in striking contrast to struc-
tural data obtained at pH 7.5, which shows the side chain
directed toward bulk solvent (3QEL). This difference in Glu235
orientation between the two structures was not previously
noted (Karakas et al., 2009, 2011). We suggest that at lower
pH, protonation of Glu106 and/or Glu235 is favored, allowing
for these residues to interact noncovalently. Glu235 and
Glu106 reside at the N termini of two helices, and ifenprodil
(and presumably 93-31) inhibits GluN1/GluN2B by restricting
domain movement. Thus, if Glu106 and Glu235 interact moreNeuron 85, 1305–1318strongly at lower pH, this could add a
further restriction to intradomain move-
ment in addition to ligand binding. Rigid
rotation of Glu235 within this structure
(3QEL) so that it forms a bidentate inter-
action with Glu106 shifts the predicted
pKa* values still further away from the
free solution values to 6.8 (Glu235) and
7.9 (Glu106). To explore the effects of
the dicarboxylate on the ligand, charge-
neutral subsets of all nearby residues
were used to generate electrostatic po-
tential surfaces (see Experimental Proce-
dures). While there was no noticeable
change on the predicted partial charges
of 93-31, the electrostatic surface poten-
tial charge centered on the ammonium
group of 93-31 was more positive in the
presence of the Glu106:Glu235 carbox-
ylic acid dimer (Figure 4C). Based on
the structural differences in Glu106 andGlu235 for crystals solved at different pH values (3JPW versus
3QEL), and the predicted pKa* values, the amino acid pair
Glu106:Glu235 is a strong candidate for constituting a pH
sensor that influences 93-31 binding and inhibition.
Carboxylic Acid Dimers: An Unrecognized Interaction
within Proteins
The interaction between Glu106 and Glu235 at pH 5.5 in
3JPW is somewhat unusual and suggestive of a hydrogen
bonded carboxylic acid dimer (Figures 4B and 4C). This bi-
dendate dimeric form is well-represented in small-molecule
crystallography, with the Cambridge crystallographic database
(Allen 2002) reporting 2,000 cases when queried with Mer-
cury/Motif (Leiserowitz et al., 2002; Macrae et al., 2006). In
addition, in the appropriate solvent and gas phase, carboxylic, March 18, 2015 ª2015 Elsevier Inc. 1309
Figure 4. Mutation of Candidate Residues
for Controlling the pH Sensitivity of 93-31
Binding
(A) Acidic (red) and basic residues (blue) are shown
within 12 A˚ of the ifenprodil (depicted as cyan
sticks) binding site. We estimated the intraprotein
pKa values using PropKa 3.1 (see Experimental
Procedures and Table 2), and subsequently
mutated these residues to Ala to determine their
effect on the pH sensitivity of the IC50 for 93-31.
GluN1 is shown as gray, and GluN2B is orange.
(B) Glu106 and Glu235 are close enough to
interact at the lower pH of 5.5 (light blue, 3JPW),
but not at pH 7.5 (green, 3QEL) in GluN2B crystal
structures.
(C) (Top panel) Distances in A˚ are shown sepa-
rating Glu235 and Glu106 in the crystal structure
for GluN2B solved at pH 5.5 (PDB code 3JPW),
implying O-protonation and O-H hydrogen bonds
of 1.6 A˚ and 1.9 A˚, respectively. (Bottom panel)
Electrostatic potential surfaces on a truncated 93-
31 binding site (in red circle) were predicted with
Spartan using the PM6 basis set. 93-31 is more
positive (blue) in the presence of the carboxylic
acid dimer between E106 and E235 (left) compared
to the noninteracting charged state (right). Both
PM6 models are charge neutral, each containing
an equal number of cationic and anionic side
chains surrounding the binding site.
(D) Occupation of the tunnel by n-butyl of 93-31
potentially orients the hydroxyl for interaction with
Glu106.
(E) A similarly scoring docking pose of the R-
enantiomer of 93-31 (93-88) orientates the hy-
droxyl away from Glu106 and toward the tunnel.
See also Figure S3.dimers are readily formed (Tzeli et al., 2011; Shipman et al.,
2007). However, scanning the PDB for residues with the dimer
geometry revealed 41 structures exhibiting a similar interac-
tion between carboxylate side chains, none of which were dis-
cussed, with the exception of a carboxylic acid dimer be-
tween retinoic acid and Glu121 in a quintuple mutant of the
cellular retinoic acid binding protein (3CWK; Vasileiou et al.,
2009). The present results suggest that carboxylic acid dimers
may represent a hitherto-unrecognized functional interaction
in proteins.1310 Neuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc.Potential Role of Glu106:Glu235 in
pH-Sensitive 93-31 Inhibition
Inspection of 93-31 docking poses in the
GluN1/GluN2B ATD heterodimer at pH
7.5 suggests several possible roles for
GluN2B-Glu106 and -Glu235 in terms of
conferring pH sensitivity. The top scoring
docking results suggest that Glu106 can
hydrogen bond with 93-31, while Glu235
is close enough to interact electrostati-
cally with the ligand (Figures 4B and 4C).
Occupation of the tunnel by n-butyl ori-
ents the hydroxyl for a favorable interac-
tion with Glu106, the orientation of whichwe propose is pH sensitive (Figure 4D). Interestingly, docking
of the R-isomer of 93-31 (93-88; Figure 4E) places the n-butyl
chain outside of the tunnel and orients the hydroxyl group
away from Glu106 in similarly high-scoring poses. This docking
result is consistent with the significantly reduced pH sensitivity
of 93-88 inhibition (3.8 ± 0.7-fold shift in IC50 at pH 6.9 compared
to the IC50 at pH 7.6) versus 93-31 (10 ± 2.7-fold shift, n = 9–10,
p < 0.05, unpaired t test) when IC50 values were assessed for
both compounds in the same experiment. The exact nature of
the hydrogen-bonding environment is difficult to predict using
Table 2. pH Dependence for 93-31 IC50 of Selected Mutants of GluN1/GluN2B and Estimates of the Corresponding Solution versus
Intraprotein pKa Values
Mutation
Solution
pKaa
Intraprotein
pKa* a
IC50 mM, Maximum %
Inhibition at pH 7.6 (N)b
IC50 mM, Maximum %
Inhibition at pH 6.9 (N)b IC50(7.6)/IC50(6.9)
GluN2Bc – – 1.8 mM, 76% (32) 0.19 mM, 83% (23) 9.5
GluN2B(D77A) 3.9 4.1 68 mM, 100%d (6) 5.9 mM, 93% (10) 12
GluN2B(K79A) 10.5 11.1 2.7 mM, 70% (8) 0.36 mM, 68% (10) 7.5
GluN2B(D104A) 3.9 4.7 110 mM, 100% (6) 19 mM, 100% (8) 5.8
GluN2B(E106A) 4.3 7.0 11 mM, 96% (7) 4.3 mM, 80% (9) 2.6
GluN2B(E106Q) 4.3 7.0 8.7 mM, 70% (8) 3.2 mM, 91% (8) 2.7
GluN2B(E106D) 4.3 7.0 4.4 mM, 91% (7) 1.1 mM, 85% (7) 4.0
GluN2B(D113A) 3.9 5.8 6.2 mM, 55% (9) 1.3 mM, 55% (7) 4.8
GluN2B(D136A) 3.9 4.8 5.4 mM, 85% (10) 0.55 mM, 74% (9) 9.8
GluN2B(K137A) 10.5 7.8 28 mM, 95% (7) 1.8 mM, 84% (10) 16
GluN2B(D138A) 3.6 3.3 2.6 mM, 77% (10) 0.18 mM, 86% (8) 14
GluN2B(D206A) 3.6 3.1 82 mM, 100% d (9) 83 mM, 100% d (7) 1.0
GluN2B(D210A) 3.6 3.8 13 mM, 52% (7) 3.9 mM, 69% (11) 3.3
GluN2B(D211A) 3.6 2.9 7.1 mM, 75%, (9) 2.5 mM, 89% (24) 2.8
GluN2B(K215A) 10.5 9.7 3.3 mM, 63% (13) 0.29 mM, 71% (8) 11
GluN2B(K234A) 10.5 9.8 21 mM, 80% (6) 3.9 mM, 89% (12) 5.4
GluN2B(E235A) 4.3 5.1 120 mM, 100%d (13) 80 mM, 100%d (7) 1.5
GluN2B(E235Q) 4.3 5.1 1.2 mM, 67% (12) 0.49 mM, 73% (8) 2.4
GluN2B(E235D) 4.3 5.1 0.93 mM, 80% (7) 0.22 mM, 76% (8) 4.2
GluN2B(E106Q,E235Q) – – 9.2 mM, 71% (7) 4.7 mM, 98% (4) 2.0
GluN2B(E106D,E235D) – – 2.2 mM, 79% (8) 1.1 mM, 74% (10) 2.0
GluN2B(E236A) 4.3 5.7 6.9 mM, 90% (10) 0.85 mM, 93% (18) 14
GluN1(R115A) 12.5 11.2 4.3 mM, 68% (15) 2.8 mM, 83% (12) 1.5
GluN1(D130A) 3.9 4.7 3.7 mM, 76% (8) 2.4 mM, 96% (10) 1.5
GluN1(K131A) 10.5 10.5 2.3 mM, 86% (7) 0.51 mM, 89% (7) 4.6
GluN1(H134A)e 6.0 3.2 0.7 mM, 157%e (17) 0.8 mM, 147%e (14) 0.9
GluN1(G112A) – – 4.6 mM, 73% (16) 1.2 mM, 80% (29) 3.8
GluN1(G112V) – – 18.7 mM, 85% f (7) 18.5 mM, 85%f (5) 1.0
apKa values in free solution were compared to those derived from the GluN1/GluN2B ATD heterodimer solved at pH 7.5 with coordinates from PDB
code 3QEL. *Intraprotein pKa predicted with PropKA 3.1(Olsson, 2011).
bIC50 values to two significant figures for inhibition of GluN1/GluN2B expressed in Xenopus oocytes were determined as described in the Experimental
Procedures from composite 93-31 inhibition curves. The fitted maximal inhibition is given as percent, and the number of oocytes is given in parenthe-
ses.
cData for compound 93-31 are reproduced from Table 1 and included here to facilitate comparison.
dMaximum inhibition was fixed to be 100%.
eThis mutation converted 93-31 into a potentiator, with EC50 and maximal potentiation given.
fMaximum inhibition was fixed to be 85%.docking programs, due to the absence of solvent and the multi-
plicity of protonation states. However, these results suggest that
a favorable network of interactions may exist under acidic condi-
tions between 93-31, Glu106, and Glu235. Consistent with this
idea, NP10075, a pH-sensitive GluN2B-selective antagonist
recently reported by Wang et al. (2014), docks in poses similar
to those of 93-31 (Figure S3). Whereas NP10075 lacks the side
chain of the 93-series that exploits the GluN1 tunnel, the bulky
piperazine moiety nevertheless appears to orient the hydroxyl
to interact with Glu106 in similar fashion to 93-31. This raises
the idea that the pH sensitivity of NP10075 also reflects an inter-
action with the pH-sensitive dicarboxylate Glu106:Glu235 dimer.Glu235 also lies in close proximity to Glu106 in the ligand-
bound structure such that it could be responsible for raising
the pKa of Glu106, leading to protonation at pH 6.9. To directly
assess this prediction, we mutated all residues within 12 A˚ of
the ifenprodil binding pocket to alanine, and measured the pH
sensitivity of 93-31 potency. A large number of these mutations
modestly perturbed the pH sensitivity of 93-31 inhibition
(Table 2). However, among these, three GluN2B mutations
(E106A, E206A, and E235A) eliminated the pH dependence of in-
hibition by 93-31, two of which show pH-sensitive conforma-
tions. The third residue (Glu206) is close enough to interact
with Glu235, and replacement with a neutral residue may renderNeuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc. 1311
the local microenvironment favorable to maintenance of a nega-
tive charge on Glu106 and Glu235 at both pH values, preventing
carboxylic acid dimer formation. Furthermore, both E206A and
E106A substantially increased IC50 values at both pH values,
perhaps reflective of a larger structural rearrangement that re-
duces 93-31 binding, thereby obscuring the pH effect.
Mutations at Glu106 and Glu235 produce modest effects on
inhibition by 93-31 at pH 7.6, but stronger effects at pH 6.9.
For example, GluN2B(E106A) increased the IC50 by 6-fold at
pH 7.6 (11 mM) and by 23-fold at pH 6.9 (IC50 4.3 mM). This is
consistent with the idea that the potency of 93-31 could be
dependent on the ionization state of Glu106, which, given the
shift of its pKa, can be influenced by modest reduction in pH
to 6.9 in the ischemic penumbra. We mutated this glutamate to
glutamine to remove the ionizable carboxylate, and found that
GluN2B(E106Q) shifted IC50 values more at pH 6.9 (17-fold)
than at pH 7.6 (5-fold). Isosteric replacement of ionizable Glu
with the protonatedGln presumably allows for a weak interaction
between these residues at both pH values, partially eliminating
the pH sensitivity. The double mutant GluN2B(E106Q,E235Q)
showed the same effect as GluN2B(E106Q) alone (Table 2), sug-
gesting that themain effect is mediated by Glu106.We predicted
that shortening the side chain by converting glutamate to aspar-
tate should also diminish the pH sensitivity if there are tight
geometrical constraints on interactions between the two closely
spaced glutamates. Consistent with this prediction, introduction
of an aspartate in GluN2B(E106D) diminished the pH sensitivity
of 93-31 inhibition to 2.4- and 5.8-fold for pH 7.6 and 6.9, res-
pectively. Again, introduction of the double mutation GluN2B
(E106D,E235D) resulted in an effect similar to GluN2B(E106D),
suggesting Glu106 was the primary determinant. In summary,
the differential position of Glu235 in the crystal structures solved
at two pH values, the predicted shift in the Glu106:Glu235 dimer
pKa*’s to values that change ionization as pH drops to 6.9, and
the mutagenesis-induced change in pH sensitivity of 93-31 all
suggest that Glu106 and Glu235 are candidates for controlling
the pH sensitivity of 93-31 binding.
Potential Role of Other pH-Sensitive Binding-Site
Residues
Several other acidic residues revealed substantially altered pKa
values (Asp113, Lys137, and His134) or pH sensitivity (Asp206,
Asp 210, and Asp211). GluN2B-Asp113 (pKa 5.8; Figure 2D) is
close enough to form hydrogen bonds with the backbone amide
hydrogen of GluN2B-Asp138 and the side chain of GluN2B-
Ser141, and form a water-bridged interaction with GluN1-
Tyr109. The predicted increase in pKa* for Asp113 could lead
to fractional protonation under acidic conditions, which should
alter the hydrogen bonding networks associated with GluN2B-
Asp138 and GluN1-Tyr109. If the interaction is reciprocal and fa-
vors protonation of a fraction of Asp113 side chains, binding of
93-31 may be facilitated and stabilize the protonated state (i.e.,
raising the pKa). In this context, it may be noted that a string of
Glu and Asp side chains form a negatively charged layer above
the ifenprodil binding site (Figure 4A; GluN2B residues 236,
235, 104, 106, 136, and 113). Each of these residues experiences
an increase in predicted pKa* relative to the free solution. The
proposed Glu106:Glu235 pH sensor resides at one end of the1312 Neuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc.layer. Any change in the protonation state of the dicarboxylate
sensor could significantly influence this cluster of residues, al-
lowing them to serve as a trigger for perturbation of local con-
formation and ionization state as part of the binding event. The
close clustering of acidic residues has been implicated in the
pH-sensing mechanism of the acid sensing ion channel-1 pro-
tein (Jasti et al., 2007). Similarly, there is a cluster of cationic
GluN1 residues (343, 115, and 134; Figure 3A), the intraprotein
pKa*s of which are predicted to decrease relative to free solu-
tion. Thus, the ligand resides between electrostatic layers of
opposite charge, in a situation that may render ligand binding
sensitive to changes in both ligand configuration and pH. The
complexity of this region is highlighted by the mutation of
GluN1-His134 to Ala, which converts 93-31 into a pH-insensitive
positive allosteric modulator (Table 2).
Three mutations at residues near the GluN1/GluN2B interface
(Asp206, Asp210, and Asp211) substantially altered the pH
sensitivity of 93-31 inhibition (Table 2). GluN2B-Asp210 is close
enough to interact with GluN1-Arg323. Similarly, GluN2B-
Asp206 can interact with GluN1-Lys322, although the large
decrease in potency at both pH 6.9 and 7.6 for GluN2B(D206A)
suggests a larger disturbance of 93-31 binding. Lastly, Asp211
interacts with the positive N terminus of an a helix. Whereas
the pKa predictions suggest pH-induced effects are unlikely at
pH 6.9, protonation of any of these residues could weaken or
abolish their respective interactions.
Neuroprotection by pH-Dependent GluN2B-Selective
Antagonists
In order to test the hypothesis that a pH drop associated with
ischemic tissue engages the pH-sensitive enhanced potency
of GluN2B antagonists in vivo for neuroprotection, we evaluated
the efficacy of the pH-sensitive inhibitors on infarct volume
following transient occlusion of the middle cerebral artery
(MCAo) in mice. We selected two structural isomers that differed
only in the N-alkyl chain, compound 93-31, which contains an n-
butyl and is pH sensitive, and compound 93-97, with less pH
sensitivity and an iso-butyl substituent (Table 1). Each com-
pound was administered by intracerebroventricular (i.c.v.) injec-
tion directly into the lateral ventricle 20 min prior to initiation of
transient focal ischemia by MCAo. Figures 5A and 5B shows
both the method of determining the infarct volume and that
i.c.v. administration of 93-31 produced dose-dependent and
robust 59% reduction in infarct volume compared to vehicle.
However, compound 93-97 was ineffective as a neuroprotectant
with no reduction in infarct volume, consistent with our in vitro
studies showing that the potency of 93-97 is relatively insensitive
to pH. That is, 93-97 potency is similar to that of 93-31 at phys-
iological pH 7.35 (93-31 IC50 = 2.2 mM, 93-97 IC50 = 4.8 mM, n =
5–6), but not enhanced sufficiently at pH 6.9 (Table 1) to render it
efficacious in penumbral regions (Figures 5A and 5B).
Prior generations of competitive and noncompetitive NMDAR
antagonists cause a variety of off-target and on-target adverse
effects that prevented clinical development, including motor
dysfunction, cognitive impairment, and psychotomimetic effects
including hallucinations, paranoia, disorganized thought, and
blunted affect (Lees et al., 2000; Sacco et al., 2001; Diener
et al., 2002; Rowland, 2005; Wood, 2005; Muir, 2006; Blagrove
Figure 5. 93-31 Is Neuroprotective against
Transient Ischemia without Side Effects
(A) (Left panel) A single mouse brain section (2mm)
obtained 24 hr post-ischemia and stained with
TTC as described in Experimental Procedures.
(Right panel) The same mouse section is shown
with areas for which the TTC intensity that is 20%
below threshold selected from contralateral cortex
(blue circle) is shown as red.
(B) Summary of MCAo infarct volume results from
treatment groups injected with (in pmols) 93-31
(50, 500), or 93-97 (500) compound by i.c.v., or an
equivalent PBS volume (vehicle) 20 min before
MCAo. *p < 0.005 (ANOVA, Tukey post hoc test),
number of mice/group indicated.
(C) Dose-response curve for 93-31 administered
IP 20 min preceding MCAo in mice (solid symbols)
or 30 min after MCAo reperfusion (open symbol).
Infarct volume was determined by TTC staining as
described in (A) and Experimental Procedures.
Number of mice/group is indicated; all measure-
ments were significantly different (p < 0.05) from
vehicle (ANOVA and Dunnett’s test).
(D) Horizontal locomotor activity (cumulative 2 hr
period) following i.p. administration of the indi-
cated drug and dose in rats is shown. n = 6–8.
Higher doses of Ro 25-6981 and ketamine were
not tested.
(E) 93-31 failed to produce PCP-associated lever
responding in rats trained to discriminate PCP
from saline. n = 6 for all except 4 mg/kg PCP (n = 3)
and 30 mg/kg 93-31 (n = 5).
(F) The highest dose tested in the PCP discrimi-
nation study, 56 mg/kg, significantly suppressed
response rates in the same subjects, suggesting
behaviorally active doses were tested (see
Experimental Procedures). n = 6 for all. All data
presented as mean ± SEM. See also Figure S4 and
Table S5.et al., 2009). Although the GluN2B-selective class of antagonists
are better tolerated than competitive antagonists or channel
blockers, they are not necessarily free from on-target side ef-
fects (Chaperon et al., 2003; De Vry and Jentzsch, 2003; Yurke-
wicz et al., 2005; Nicholson et al., 2007; Preskorn et al., 2008;
Nutt et al., 2008). Our working hypothesis is that enhanced pH
sensitivity should increase the therapeutic ratio (TR) to enable
efficacious dosing for neuroprotection in ischemic penumbral re-
gions surrounding the infarct (pH 6.9), with reduced inhibition of
GluN2B receptors in normal brain (pH 7.4). That is, the pH sensi-
tivity of the NMDAR antagonist should lower the potential for
on-target side effects. To determine a TR (the ratio of ED50 for ef-
ficacy versus side-effect studies) for 93-31 as a neuroprotectant,
we completed additional MCAo studies in which 93-31 showed
potent neuroprotection during ischemia, reducing infarct vol-
umes up to 50% with an apparent ED50 value of <1 mg/kg (Fig-
ure 5C). For these studies, 93-31 was dosed intraperitoneally
(i.p.) 20min prior to transient ischemia byMCAo. Further, admin-
istration of 93-31 (10 mg/kg IP) 30 min post-MCAo also reduced
infarct volume to a similar extent (open symbol, Figure 5C). PK
studies in surrogate mice support drug exposures in brain
consistent with potency at low pH (Table S5; Supplemental
Experimental Procedures).We subsequently made three measurements of potential on-
target dose-limiting side effects. First, we evaluated effects of
93-31 on locomotor activity and found no significant effects on
horizontal activity at doses up to 300mg/kg compared to vehicle
(4,415 ± 479, n = 24) over 2 hr following 1 hr habituation, in
contrast to the channel blockers aptiganel and ketamine. The
GluN2B-selective antagonists ifenprodil and Ro 25-6981 re-
duced and increased locomotor activity, respectively, at high
doses (Figure 5D). Second, we evaluated the effects of 93-31
in a rotorod test. Both the noncompetitive NMDAR antagonist
(+)MK-801 and ifenprodil impaired performance, exhibiting
strong reductions in latency to fall (vehicle 140 ± 13 s, n = 12;
0.6 mg/kg [+]MK-801 3 ± 2 s, n = 5; 30 mg/kg ifenprodil 35 ± 6
s, n = 5). By contrast, there was no significant effect of 93-31
(108 ± 14 s, n = 6) nor 93-97 (117 ± 19 s, n = 6) on rotorod perfor-
mance at 30 mg/kg (Figure S4). Third, we tested the ability
of GluN2B-selective NMDAR blockers to be recognized by
rodents trained to discriminate the noncompetitive channel
blocker PCP from saline. Trained animals were administered
93-31, PCP, or saline on test days. Interestingly, 93-31 failed to
substitute for PCP in this paradigm (Figure 5E), suggesting this
compound is devoid of psychotomimetic effects at the doses
tested. At the highest dose (56 mg/kg), there was a significantNeuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc. 1313
depression in lever-pressing behavior, indicating that behavior-
ally active doses were tested and therefore the lack of PCP-
like effects was not attributable to an inadequate dose range
(Figure 5F). Of these four behaviors (locomotor activity, rotorod,
PCP discrimination, and lever pressing), we identified only one in
which 93-31 caused significant effects at doses of 30 mg/kg
or higher. From the ED50 for neuroprotection (<1 mg/kg) we
calculate a TR for neuroprotection in rodents following IP admin-
istration of >30 for the pH-sensitive 93-31 GluN2B inhibitor, a
value considerably higher than that estimated for neuroprotec-
tion in the literature for ifenprodil and dizolcilpine (TR% 1; Hat-
field et al., 1992; Bertorelli et al., 1998; Dawson et al., 2001;
Xiao et al., 2004) and CP-101,606 (TR 4; Yang et al., 2003,
Nicholson et al., 2007).
DISCUSSION
Two important findings emerge from this study. First, these
data provide molecular insight into the nature of inhibition pro-
duced by therapeutically relevant GluN2B-selective modulators
that bind to the GluN1/GluN2B heterodimer interface of the
amino terminal domain (Karakas et al., 2011; Burger et al.,
2012; Karakas and Furukawa 2014; Lee et al., 2014). Our
data suggest that changes in the 93-31 association/dissocia-
tion rates at acidic pH reflect an altered configuration around
the binding pockets when ionizable residue(s) in helix-3 and he-
lix-8 are protonated. The juxtaposition of ionizable side chains
by tertiary protein structure has been suggested to shift intra-
protein pKa values (Harris and Turner 2002; Jasti et al., 2007;
Ritschel et al., 2009; Bombarda and Ullmann 2010; Sussman
et al., 2013), creating a carboxylate-based pH sensor for ligand
binding within the amino-terminal domain that docking studies
suggest directly interacts with 93-31. Interestingly, an interact-
ing carboxylate pair has recently been suggested to form the
pH sensor of a Ca2+ leak channel (Chang et al., 2014). While
the Ca2+ leak channel dicarboxylate pair does not form the
classic reciprocal hydrogen bonding of a carboxylic acid dimer,
it nonetheless alternates between multiple states with varying
pH, including protonation of both side chains. In addition to
ionization of the GluN2B glutamate residues impacting 93-31
binding rates, it is also possible that occupancy of the binding
site by different propanolamines (Table 1) can differentially
impact position and pKa of these residues. Whereas data sug-
gest that most of the pH sensitivity is derived from changes in
binding rates of 93-31, it is possible that some pH sensitivity re-
flects the ability of 93-31 binding to bring about downstream
protein conformation changes that govern efficacy (Low
et al., 2003; Gielen et al., 2008).
Second, the development of GluN2B inhibitors with pH-
dependent potency is important, considering problems with
past clinical programs centered on neuroprotection by NMDAR
antagonists. Data presented here show that NMDAR antago-
nists can be designed that provide enhanced receptor
blockade during a decrease in extracellular pH, resulting in
neuroprotection in acidic ischemic tissue without untoward
side effects. This is because the increased potency in ischemic
tissue reduces the concentration needed for neuroprotection
below that which will cause effects at normal pH in healthy1314 Neuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc.brain. Decreased extracellular pH universally accompanies
ischemic injury and TBI (Mutch and Hansen, 1984; Smith
et al., 1986; Nedergaard et al., 1991; Katsura et al., 1992; Kat-
sura and Siesjo, 1998), suggesting this strategy may be appli-
cable to acute neurodegeneration under a wide range of in-
sults. Our application of this concept to the well-tolerated
class of GluN2B-selective NMDAR antagonists further in-
creases the likelihood that antagonists with these properties
will be clinically viable for indications with synaptic or interstitial
acidic pH changes. This context dependence enhances the TR
for such pH-sensitive compounds. We calculate from the ef-
fects on infarct volume following ischemia and from the dose-
effect relationship in healthy animals using PCP discrimination
studies that 93-31 has a TR greater than 30, which is higher
than that which can be calculated from the literature for
GluN2B-NMDAR antagonists acting as neuroprotectants (see
above).
In light of these data, the results of clinical studies with CP-
101,606, which nearly reached significance for a TBI trial despite
a lengthy time window for drug administration (8 hr) postinjury,
are encouraging. CP-101,606 (Mott et al., 1998) and other
GluN2B antagonists lack substantial pH sensitivity (Table S6),
and thus it is intriguing to speculate that a compound with similar
actions as CP-101,606 but with the additional enhanced pH
sensitivity might be clinically successful. If the concept of
context-dependent inhibition is coupled with modern clinical trial
designs that allow rapid, blinded trials by first responders within
hours of ischemic onset or traumatic insult (Saver 2013), there
is excellent likelihood that the well-known neuroprotective po-
tential of NMDAR antagonists can impact clinical outcomes
in ischemia and TBI. This proof-of-concept molecule demon-
strates the utility of this strategy and creates a strong precedent
for exploiting the pHdependence of theGluN2B class of NMDAR
antagonists for brain injury involving overactivation of NMDARs
and extracellular acidification.EXPERIMENTAL PROCEDURES
Voltage-Clamp Recordings from Transfected HEK Cells
HEK293 cell preparation and transfection were conducted (see Supplemental
Experimental Procedures) as described previously (Yuan et al., 2009).
Following transfection of GluN1-1a (hereafter GluN1, GenBank U11418) and
GluN2B (GenBank U11419), whole-cell voltage-clamp recordings were con-
ducted on transiently transfected HEK cells using an Axopatch 200B amplifier
(Molecular Devices, Union City, CA, USA). Current responses were digitized at
40 kHz by pClamp10 software (Molecular Devices). Recordingswere filtered at
8 kHz using an eight-pole Bessel filter (3 dB; Frequency Devices, Haverhill,
MD, USA). Thin-walled borosilicate glass capillary tubes (World Precision In-
struments, catalog number TW-150F-4, Hamden, CT, USA) were used to
form recording micropipettes for whole-cell currents. All recording micropi-
pettes were filled with an internal solution containing (in mM) 110 D-gluconic
acid, 110 CsOH, 30 CsCl, 5 HEPES, 5 BAPTA, 4 NaCl, 2 MgCl2, 2 NaATP,
0.5 CaCl2, and 0.3 NaGTP (pH 7.35). Cells were bathed at 23
C in external so-
lution that contained (in mM) 150 NaCl, 10 HEPES, 3 KCl, 0.5 CaCl2, 0.01
EDTA, and 30 D-mannitol at pH 7.6 or pH 6.9. All recording solutions were
made from external solution and recordings were performed at holding poten-
tials of 60 mV. Rapid solution exchange for macroscopic recordings was
accomplished with a two-barrel theta glass pipette controlled by a piezoelec-
tric translator (Burleigh Instruments, Fishers, NY); 10%–90% open tip solution
exchange timeswere under 1ms, and solution exchange around thewhole cell
was under 5 ms (Vance et al., 2011). Assuming 93-31 follows the law of mass
action, the exponential time course for the onset of inhibition should have a tau
described by Equation (1),
TauONSET = 1=ðkON½concentration+ kOFFÞ; (Equation 1)
where kON and kOFF are themicroscopic association and dissociation rate con-
stants. From this relationship we can determine the association rate (kON) from
the slope of linear plot of 1/TauONSET and concentration (Figure 1D) and the
dissociation rate (kOFF) from the intercept (KD = kOFF/kON).
Two Electrode Voltage-Clamp Recordings from Xenopus Oocytes
All protocols involving animals were approved by the Emory University and Vir-
ginia Commonwealth University IACUC. Stage V–VI Xenopus laevis unfertilized
oocytes purchased from Ecocyte (Austin, TX), and were injected with 3–5 ng of
GluN1 and 7–10 ng of GluN2B cRNAs, and incubated in Barth’s solution at
18C. Two electrode voltage-clamp recordings were made 2–7 days postin-
jection at a holding potential of –40 mV using two Warner OC725B two-elec-
trode voltage-clamp amplifiers (23C). Oocytes were perfused with a solution
of (in mM) 90 NaCl, 1 KCl, 10 HEPES, 0.01 EDTA, and 0.5 BaCl2; pH was
adjusted to 7.6 by addition of NaOH, and subsequently lower pH values by
addition of HCl to ensure constant concentration of Na+ in all solutions. Con-
centration-response inhibition curves were obtained by bath application of
increasing concentrations of antagonist in the presence of 50–100 mML-gluta-
mate and 30 mM glycine until steady-state conditions were reached (1–6 min
typically, 15 min in some cases). Recordings were made from three to ten oo-
cytes per experiment from two to six experiments. The percent responses for
the composite data were fit by Equation (2),
Percent Response= ð100minimumÞ
.
1+ ð½concentration=IC50ÞnH

+minimum;
(Equation 2)
where minimum is the residual percent response in saturating concentration
(constrained toR 0) of the experimental compounds, IC50 is the concentration
of antagonist that causes half maximal inhibition, and nH is a slope factor of the
inhibition curve.
Triheteromeric GluN1/2A/2B receptors were expressed in Xenopus oocytes
using the constructs and method described in Hansen et al. (2014) (see Sup-
plemental Experimental Procedures).
Docking of 93-Series Compounds
Compounds 93-31, 93-97, and NP10075 were built in Maestro 9.2 (Schro-
dinger suite) and docked using the OPLS2005 force field and Glide Induced
Fit docking protocol (Sherman et al., 2006). The atomic coordinates for
GluN1/GluN2B amino terminal domain cocrystallized with ifenprodil was
used as the input structure (3QEL; Karakas et al., 2011). The binding site
was defined by residues within 5 A˚ of ifenprodil, which were treated as flexible.
A maximum of 100 poses per ligand was generated. Both N-protonated ste-
reoisomers and the unprotonated form were docked. The unprotonated forms
were docked with N-inversion enabled. All poses were also subsequently
scored with MM-GBSA binding energy calculations (Prime version 3.1). VMD
1.9 (Humphrey et al., 1996) was used for visualization, while prediction of
altered pKa values was carried out with the VMD PropKa plugin (Olsson
2011). The semiempirical PM6 electrostatic potential evaluation of the
GluN1/GluN2B ligand binding site and the associated protein side chains
was performed with Spartan 10, version 1.1.0., fromWavefunction Inc. (Young
2001; http://www.wavefun.com/products/products.html; accessed October
9, 2013).
In Vivo Models of Transient Focal Ischemia
Transient focal cerebral ischemia (30 min) was induced in mice by intraluminal
middle cerebral artery occlusion (MCAO; Junge et al., 2003). Male C57BL/6
mice (3–5 months old, Jackson Labs) were anesthetized with 2% isoflurane
in 98% O2. We avoided the use of ketamine, given its confounding neuropro-
tective channel-blocking actions on NMDARs (Hamill et al., 2009). The rectal
temperature was monitored and mouse temperature maintained at 37C
(range 36.5–37.5) with a homeothermic blanket. Blood pressure was not moni-
tored or controlled. Relative changes in regional cerebral blood flow weremonitored with a laser Doppler flowmeter (Perimed); the Doppler probe was
glued to the skull 2 mm posterior and 4–6 mm lateral of the bregma. Only an-
imals with reduction in blood flow to 20% and clear recovery of blood flow
were included in the study. An 11 mm 5-0 Dermalon or Look (SP185) black
nylon nonabsorbable suture with the tip flame rounded was introduced for
30 min into the left internal carotid artery through the external carotid artery
stump until monitored cerebral blood flow was reduced <20% (at 10.5–
11 mm of suture insertion). Only animals with sustained reduction in blood
flow to <20% for 30 min and clear recovery of blood flow to >90% following
removal of the intraluminal suture were included. After 24 hr, the brain was
removed and cut into 2 mm sections. The lesion was identified with 2%
2,3,5-triphenyltetrazolium chloride (TTC) in PBS at 37C for 20 min and the
infarct area measured using NIH IMAGE (Scion Corporation, Beta 4.0.2
release). The area of the lesion, as identified by digital threshold reductions
in TTC staining 20% lower than intensity in contralateral cortex, was manually
outlined and the cubic volume of the infarct size determined. A ratio of the
contralateral to ipsilateral hemisphere section volume was multiplied by the
corresponding infarct section volume to correct for edema. Drug was admin-
istered by intraperitoneal (i.p., 3 mL/kg) or by i.c.v. (1 ul) injection 10min before
initiation of surgery (i.e., 20 min before vessel occlusion) or 30 min after
removal of the intraluminal suture. I.c.v. injections were made into the right
ventricle (2 mm post., 1 mm lat. of the bregma, needle inserted 3 mm). Com-
pound was formulated in 1:1 DMSO:phosphate buffered saline (pH 7.4) for IP
injection and 1:10 DMSO:phosphate buffered saline (pH 7.4) for i.c.v. Those
performing the surgical procedure and analysis were blinded to the identity
of the treatment.
Measurement of Locomotor Activity, Rotorod Activity, and PCP
Discrimination
Male Sprague-Dawley rats (100–150 g) were placed in activity monitoring
boxes for a 1 hr habituation period prior to drug testing. At 1 hr, monitoring
was interrupted to inject animals IP with various doses of drug in 50% v/v
DMSO:saline. Animals were returned to the cage, and total locomotor activity
was monitored for the next 2 hr. The total number of light beam breaks in the
cage (horizontal and vertical) was automatically determined by a computer
and results averaged for each drug. An ANOVA followed by Dunnett’s test
was used to compare total horizontal activity of drug doses to vehicle
controls.
For rotorod, male C57BL/6 mice (>90 days old) were tested using a four-
chamber Rotamax 4/8 rotorod (Columbus Instruments, Columbus, OH). The
test was initiated by placing mice on a rotating rod (5 rpm) that was 3.8 cm
diameter by 8 cm wide and suspended 30 cm from the floor of a chamber.
After 10 s the rotation was accelerated from 5 to 35 rpm over a 5 min period.
The latency to fall (sec) was recorded automatically with a light-activated
sensor in the bottom of the chamber. Animals were trained four times with
an intertrial interval of 25 min, each day for 2 days. On day 3 mice were
randomly assigned to groups and administered compound or vehicle (i.p.;
47.5% DMSO, 47.5% saline, 5% DMA). Twenty minutes after drug adminis-
tration the mice were tested as before with an intertrial interval of 25 min
and latency to fall recorded. Those performing the study were blinded to
the identity of the treatment group.
To evaluate the psychotomimetic effects of the test compounds, six adult
male Sprague Dawley rats (Charles River, Wilmington, DE) were trained to
discriminate administration of 2.0 mg/kg PCP from saline injections (Balster
and Willetts 1988). They were singly housed with free access to water under
a 12 hr light/dark cycle. Subjects were maintained at 85%–90% free feeding
weight with food access (Harlan Teklad Rodent Diet, Williamston, IL) limited
to postsession periods to motivate lever pressing for food. The subjects
were trained daily (Monday through Friday) in 30 min sessions in standard
two-lever operant conditioning chambers (MedAssociates, St. Alban, VT).
Completion of 32 consecutive responses (fixed ratio 32; FR 32) on the
appropriate lever resulted in reinforcement with delivery of a 45 mg food pel-
let (P.J. Noyes Company, Inc., Lancaster, NH). Responding on the incorrect
lever reset the FR count toward pellet delivery. PCP and saline were admin-
istered IP under a double alternation schedule (e.g., drug, drug, saline, sa-
line) 15 min prior to the beginning of the session. During sessions, a white
stimulus light located centrally above each lever was illuminated. TestNeuron 85, 1305–1318, March 18, 2015 ª2015 Elsevier Inc. 1315
sessions were conducted up to twice weekly when the subjects met the
following criteria on the four preceding training sessions (two PCP and
two saline): (1) first FR completed on the correct lever, and (2) greater
than 85% correct lever responding over the entire session. During test ses-
sions, completion of 32 consecutive responses on either lever resulted in the
delivery of food.
Rats were tested at 93-31 doses of 1, 3, 10, 30, and 56 mg/kg administered
IP, 30 min presession; various doses of PCP were tested in the same animals
for comparison. Data were evaluated by calculating the mean percentage of
responses on the PCP-associated lever and the overall mean response rate.
For sessions in which a subject’s responding was less than 0.05 resp/s, the
percent PCP lever responding was excluded from determination of the group
mean. Full substitution for PCP was defined as greater than 80%PCP lever re-
sponding, while partial substitution was defined as producing between 20%
and 80% PCP lever responding.
Chemistry
The synthetic reaction schemes for all 93-series compounds can be found in
Tahirovic et al. (2008).
Statistics
Values presented are mean ± SEM, and are compared using Student’s paired
or unpaired t test, and ANOVAwhere appropriate. The level of significancewas
chosen as 0.05.SUPPLEMENTAL INFORMATION
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